In May 2013, the patient did not have any clinical manifestations associated with cryptococcal infection. or new presentation of cryptococcal disease after rapid immune restoration. In patients with human immunodeficiency computer virus (HIV)-1 contamination, this immune restoration is driven by anti-retroviral therapy (ART). HIV-associated C-IRIS occurs AZD3514 in two forms: 1) paradoxical C-IRIS in patients diagnosed with cryptococcosis before ART who initially respond to antifungal therapy but then deteriorate or develop new clinical disease associated with ART-mediated immune restoration; 2) unmasking C-IRIS in patients who present with a first episode of cryptococcal disease with atypical inflammatory manifestations after ART [1,2]. The most common manifestation of HIV-associated C-IRIS is meningitis, accounting for around 70% of cases [1]. Lymphadenopathy as well as cerebral lesions have also been described [1]. Although C-IRIS occurs in 8 to 49% of HIV-infected patients with cryptococcal disease who initiate ART [1], recurrent C-IRIS is a rare condition. Recently, worsening of central nervous system (CNS) C-IRIS after cessation or tapering of corticosteroids has been described in 3 case reports [3-5]. The patients were successfully treated with additional courses of corticosteroids or other immunomodulatory drugs such as adalimumab or thalidomide [3-5]. This form of recurrent C-IRIS appears to be associated with an unusual inflammatory reaction that requires prolonged or alternative immunosuppressive therapy. Here, we present an unusual case of recurrent C-IRIS, sequentially involving CNS and lymph nodes, in an HIV-infected patient after ART. While corticosteroids were used to control the inflammatory cerebral cryptococcomas, the lymphadenitis that developed after cessation of corticosteroids resolved without additional immunosuppressive or anti-inflammatory drugs. Rabbit polyclonal to Receptor Estrogen alpha.ER-alpha is a nuclear hormone receptor and transcription factor.Regulates gene expression and affects cellular proliferation and differentiation in target tissues.Two splice-variant isoforms have been described. == Case report == A 19-year-old HIV-1-infected man was admitted to our hospital in late July 2011 because of fever and headache for two weeks and confusion for 4 days. His CD4 cell count was 0 cell/L. Soon after his admission, he was confirmed to have cryptococcal meningitis. AZD3514 Cerebrospinal fluid (CSF) analysis demonstrated a white blood cell count of 32 cells/mm3, a glucose level of 1.4 mmol/L, a total protein level of 993.4 mg/L, and a positive India ink stain result. The baseline CSF fungal cell count under microscopy was 70 yeasts/L. CSF and blood cultures were positive for Cryptococcus spp. Brain magnetic resonance imaging (MRI) revealed bilateral basal ganglia abnormalities consistent with cerebral cryptococcomas (Figure1A, B). As per recommended clinical practice guidelines, he was treated with amphotericin B (AmB, 0.7 mg/kg per day intravenously) plus flucytosine (100 mg/kg per day in 4 divided doses) for 11 weeks, followed by fluconazole (400 mg per day) maintenance therapy [6]. CSF culture was sterile two weeks after initiation of anti-cryptococcal treatment. Follow-up lumbar puncture six weeks after initiation of anti-cryptococcal treatment revealed an improved CSF profile (white blood cell count of 2cells/mm3, AZD3514 a glucose level of 2.9 mmol/L and a total protein level of 147.8 mg/L). ART with lamivudine, stavudine and efavirenz was introduced AZD3514 in September 2011, after six weeks on anti-cryptococcal treatment. A follow-up brain MRI, obtained 7 weeks after initiation of anti-cryptococcal therapy revealed partial resolution AZD3514 of the cerebral cryptococcomas (Figure1C). The patient was asymptomatic and discharged. Another brain MRI in February 2012 demonstrated near complete resolution of the cerebral cryptococcomas (see Additional file1). == Figure 1. == Brain MRI of the patient.Axial T2-FLAIR imaging obtained soon after admission showed abnormal hyperintensities in the bilateral basal ganglia (arrows inA) without enhancement(B). After 7 weeks on anti-cryptococcal therapy, axial T2-FLAIR images showed partial resolution of the lesion (arrows inC). Twenty-five weeks after initiation of anti-retroviral therapy and while on fluconazole maintenance therapy, axial T2-FLAIR images showed abnormal hyperintensities in bilateral basal ganglia again (arrows inD) with irregular patchy enhancement (arrows inE). After 19 days.
